Affordable Access

deepdyve-link
Publisher Website

Prognostic implications of human papillomavirus status and p16 expression in laryngeal squamous cell carcinoma.

Authors
  • Zhu, Yingying1
  • Xia, Xin1
  • Gross, Neil2
  • Dahlstrom, Kristina R2
  • Gao, Liming1
  • Liang, Zhiyong3
  • Gao, Zhiqiang1
  • Wei, Peng4
  • Liu, Chuan5
  • Li, Guojun2
  • Li, Yuncheng6
  • Chen, Xingming1
  • 1 Department of Otolaryngology-Head and Neck Surgery, Peking Union Medical College Hospital, Peking Union Medical College and Chinese Academy of Medical Sciences, Beijing, China. , (China)
  • 2 Department of Head and Neck Surgery, University of Texas MD Anderson Cancer Center, Houston, Texas.
  • 3 Department of Pathology, Peking Union Medical College Hospital, Peking Union Medical College and Chinese Academy of Medical Sciences, Beijing, China. , (China)
  • 4 Department of Biostatistics, University of Texas MD Anderson Cancer Center, Houston, Texas.
  • 5 Department of Otorhinolaryngology, The First Affiliated Hospital of Chongqing Medical University, Chongqing, China. , (China)
  • 6 Department of Otorhinolaryngology, Union Hospital, Tongji Medical College, Huazhong University of Science and Technology, Wuhan, China. , (China)
Type
Published Article
Journal
Head & neck
Publication Date
Dec 01, 2019
Volume
41
Issue
12
Pages
4151–4163
Identifiers
DOI: 10.1002/hed.25961
PMID: 31566825
Source
Medline
Keywords
Language
English
License
Unknown

Abstract

The purpose of this study was to investigate significance of HPV16 DNA/p16 for survival of patients with laryngeal squamous cell carcinoma (LSCC). HPV16 DNA and p16 status in 812 LSCC patients were determined. The survival was performed using Kaplan-Meier estimates and Cox model. Compared with HPV negativity, adjusted HRs for HPV16 positivity were 0.57, 95% CI, 0.38 to 0.87; 0.60, 0.40 to 0.88; and 0.65, 0.46 to 0.94 for disease-specific survival (DSS), recurrence-free survival (RFS), and overall survival (OS), respectively. Additionally, for p16 expression, aHRs were 0.68, 95% CI, 0.48 to 0.96; 0.72, 0.52 to 0.98; and 0.73, 0.54 to 0.99 for DSS, RFS, and OS, respectively. Finally, for combined analysis, patients with both HPV16-positivity/p16-positivity had much better prognosis than those with either negativity. Such above survivals are more significantly better in never smokers. Our findings suggest that HPV16/p16 may affect survival outcomes of LSCC patients, particularly in never smokers. © 2019 Wiley Periodicals, Inc.

Report this publication

Statistics

Seen <100 times